Hospital
Aspirus Wausau Hospital, INC.
Aspirus Wausau Hospital, INC. was paid $1.94M by Medicaid between Aug 2020 and Dec 2024, across 94 billing codes. Its largest line is 96361, Intravenous infusion, hydration; each additional hour — 13% of everything it billed.
33Billing provider infoASPIRUS WAUSAU HOSPITAL, INC.
STEVENS POINT, WI 54482
STEVENS POINT, WI 54482
33aNPI1598375271assigned 08/06/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$1.94M
24GClaims77,387
24DCodes billed94
24AFirst – last monthAug 2020 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#36 of 60
Median peer was paid$2.90M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official YANG, JERRY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 4,710 | $130K | |
| 2021 | 23,694 | $562K | |
| 2022 | 16,545 | $372K | |
| 2023 | 18,002 | $451K | |
| 2024incomplete | 14,436 | $424K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 2,228 | 1,881 | $247K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 11% | 2,296 | 1,873 | $223K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 11% | 3,479 | 2,982 | $204K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 9.7% | 1,916 | 1,674 | $188K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 9.6% | 3,168 | 2,738 | $186K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 8.7% | 3,052 | 2,654 | $168K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 8.6% | 2,595 | 2,244 | $167K |
| 80053 | Comprehensive metabolic panel | 4.1% | 5,827 | 4,868 | $79K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.3% | 973 | 866 | $64K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.4% | 1,875 | 1,575 | $47K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 574 | 512 | $38K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.7% | 534 | 451 | $32K |
82 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.4% | 5,554 | $27K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.1% | 588 | $21K |
| 87070 | 1.0% | 811 | $20K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 626 | $17K |
| 81001 | <1% | 3,034 | $12K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 849 | $12K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 260 | $10K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,555 | $9K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 724 | $9K |
| 83690 | <1% | 2,270 | $9K | |
| 81025 | <1% | 310 | $9K | |
| 84703 | <1% | 1,407 | $8K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 319 | $8K |
| 84484 | <1% | 1,176 | $8K | |
| 80061 | Lipid panel | <1% | 561 | $8K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 255 | $7K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 472 | $6K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 202 | $6K |
| 73630 | <1% | 307 | $6K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 91 | $6K |
| 74018 | <1% | 172 | $5K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 446 | $5K |
| 83605 | <1% | 819 | $5K | |
| 85610 | <1% | 309 | $5K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,367 | $4K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 186 | $4K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 41 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 67 | $4K |
| 83735 | <1% | 940 | $4K | |
| 80306 | <1% | 178 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 342 | $3K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 254 | $3K |
| 87807 | <1% | 49 | $3K | |
| 83880 | <1% | 112 | $2K | |
| 73610 | <1% | 91 | $2K | |
| 85027 | <1% | 433 | $2K | |
| 87077 | <1% | 159 | $2K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 3,370 | $2K |
| 82948 | <1% | 356 | $2K | |
| 85379 | <1% | 160 | $1K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 17 | $1K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 15 | $1K |
| 87210 | <1% | 76 | $951.00 | |
| 84439 | <1% | 45 | $825.14 | |
| 83655 | <1% | 16 | $824.10 | |
| 87088 | <1% | 161 | $689.26 | |
| 87186 | <1% | 117 | $647.52 | |
| 85007 | <1% | 257 | $596.88 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,618 | $491.75 |
| 82728 | <1% | 14 | $407.80 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,492 | $406.16 |
| 73564 | <1% | 25 | $345.85 | |
| 36415 | Collection of venous blood by venipuncture | <1% | 1,235 | $339.41 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $199.04 |
| 86850 | <1% | 13 | $190.98 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,794 | $190.26 |
| 73140 | <1% | 13 | $171.10 | |
| 82550 | <1% | 52 | $161.86 | |
| 87040 | <1% | 25 | $161.80 | |
| 86140 | <1% | 16 | $74.90 | |
| 85652 | <1% | 30 | $57.41 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 815 | $50.11 |
| 36000 | <1% | 595 | $20.85 | |
| 85018 | <1% | 15 | $19.60 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 16 | $10.37 |
| 96376 | <1% | 144 | $3.50 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 1,774 | $2.79 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 1,660 | $2.64 |
| J2704 | Injection, propofol, 10 mg | <1% | 131 | $2.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 713 | $0.54 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 295 | $0.16 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 0% | 832 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 125 | $0.00 |
| A9270 | Non-covered item or service | 0% | 133 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 30 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 31 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 51 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 62 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 16 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 137 | $0.00 |
| S0028 | Injection, famotidine, 20 mg | 0% | 14 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialYANG, JERRY (SVP & CHIEF FINANCIAL OFFICER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.